Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Long-Term Investments (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Long-Term Investments data on record, last reported at $10.0 million in Q3 2025.

  • For Q3 2025, Long-Term Investments rose 400.0% year-over-year to $10.0 million; the TTM value through Sep 2025 reached $10.0 million, up 400.0%, while the annual FY2023 figure was $107.0 million, 17.05% down from the prior year.
  • Long-Term Investments reached $10.0 million in Q3 2025 per RCUS's latest filing, down from $16.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $218.7 million in Q3 2021 and bottomed at $2.0 million in Q3 2024.
  • Average Long-Term Investments over 5 years is $99.9 million, with a median of $99.2 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: skyrocketed 8001.11% in 2021, then crashed 98.68% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $182.0 million in 2021, then dropped by 29.12% to $129.0 million in 2022, then decreased by 17.05% to $107.0 million in 2023, then tumbled by 98.13% to $2.0 million in 2024, then skyrocketed by 400.0% to $10.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $10.0 million in Q3 2025, $16.0 million in Q2 2025, and $2.0 million in Q3 2024.